« Back
Home /
mAb anti-Human bFGF

mAb anti-Human bFGF

Manufacturer	Anogen
Category	Oncology Neuroscience Neural Adhesion Molecules Antibodies By Cell Type Carcinoma Hematology Leukemia Myeloma Cell Biology Cell Culture Cytokines Western Blot ELISA Primary Antibodies By Organ Bladder Cancer Immunostaining
Type	Antibody Monoclonal
Specific against	Human
Clone	F-343
Isotype	IgG1 kappa
Applications	WB, ELISA, IS
Amount	0.1mg
Host	Mouse
Item no.	ANOG-MO-C40046A-0.1mg
Targets	FGF2
eClass 6.1	32160702
eClass 9.0	42030590
Available
Description	Mouse monoclonal antibody to human fibroblast growth factor basic (bFGF)
Target Protein	Human bFGF
Immunogen	Purified recombinant human bFGF
Purification	Protein G affinity purified
Myeloma	Sp2/0-Ag14
Light chain	Kappa
Background	Basic fibroblast growth factor (bFGF) is a pluripotent growth factor. Like other members in the large FGF family, bFGF can binds to different isoforms of FGF receptor. bFGF and it receptor forms a complex with heparin sulfate proteoglycans in extracellular matrix to trigger signaling transduction. In addition to cell growth and differentiation in normal development, the cytokine is important for wound healing, tumor development and embryonic stem cell growth.
Formulation	Lyophilized from a solution in 0.01M PBS, pH 7.2.
Reconstitution	Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.
Research Area	Cytokines and Growth Factors
Storage	Store at -20oC

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 0.1mg

available

Delivery expected until 6/17/2024